Researchers at U of M create Portmanteau Inhibitors, merging antiviral agents into one drug to reduce cost and toxicity. The new approach is less likely to develop resistance from the virus and shows promise in improving treatment outcomes for AIDS patients.
Researchers have discovered three gene variants in HIV-infected patients that may help fight off the virus and delay AIDS onset. The genes, particularly HLA-C, could be key targets for an HIV vaccine designed to boost immune system control.
A new vaginal microbicide, VivaGel, is being tested in a clinical safety trial among sexually active young women to determine its safety and acceptability. The study aims to assess the product's effectiveness in preventing HIV transmission and gather information on user experience.
A landmark study finds that HIV/AIDS patients are 11 times more likely to develop Hodgkin's lymphoma, while transplant recipients face a similar increased risk for several types of cancer. Immune deficiency is the common factor driving these higher cancer rates in both groups.
HIV's uniformly fatal outcome and absence of natural immunity pose significant hurdles for vaccine design. The authors call for increased funding for research and clinical trials to address these challenges and accelerate progress in finding an effective AIDS vaccine.
amfAR is funding research projects to better understand the social and biological factors that influence HIV treatment. Studies will explore the potential benefits of maraviroc, a new antiretroviral drug, and examine how stigma affects healthcare quality for people with HIV.
A new study by John R. Talbott finds that the number of infected prostitutes in a country is key to understanding the global spread of AIDS. The study suggests that prostitute communities can act as an engine driving infection rates to unusually high levels in the general population.
Recent studies found a decline in Kaposi sarcoma and non-Hodgkin lymphoma incidence among AIDS patients treated with HAART, associated with increased CD4 cell counts. Additionally, researchers identified the CCRK gene as potentially involved in glioblastoma multiforme development.
A randomized trial found that brand names significantly impact patient treatment decisions, with 36% changing their choice after seeing the true name. The study suggests that decision aids can help patients navigate complex medical decisions and express their personal values.
Scientists at NIAID are exploring vaccines that reduce HIV levels, delay disease progression and prevent transmission. Early research suggests T-cell vaccines may have benefits, but questions remain about their effectiveness and potential side effects.
Researchers at UCLA AIDS Institute found a peptide that enhances HIV infection, contradicting its normal protective function. The discovery could lead to the development of new tools for gene therapy using HIV-based vectors.
Researchers explore how religious leaders and congregations respond to HIV/AIDS, with a focus on the impact on black church communities. The study aims to identify existing support groups and reveal how social networks can increase self-worth and prolong lives.
AIDS researcher Dr. Edward Johnson has received a $1.8M NIH grant to study the molecular mechanics of progressive multifocal leukoencephalopathy (PML), a brain disease that kills four percent of AIDS patients worldwide. The research aims to understand how the JC virus causes PML, which can occur even in patients with well-managed AIDS.
The HIV Medicine Association strongly opposes The Gambia's use of an unproven herbal remedy for treating HIV/AIDS. The organization urges patients to resume taking their prescribed antiretroviral medications, which have been shown to save lives in Africa.
A study by Ohio University researchers found that one-third of sexually active older adults with HIV/AIDS have unprotected sex. The study suggests that more prevention efforts may be needed to target this specific group.
Researchers are exploring the effectiveness of telephone support groups for older adults with HIV. A new four-year study aims to test the benefits of this approach in treating depression and other mental health issues among seniors with HIV.
A natural ingredient in human blood has been identified as an effective blocker of HIV-1, the virus responsible for AIDS. The peptide, VIRIP, targets a conserved region in the viral envelope and remains effective against drug-resistant strains.
A call has been made for the Global Fund to prioritize funding health workers' salaries to ensure medicines are delivered to patients. The absence of skilled healthcare professionals poses a significant challenge in countries struggling with HIV, Tuberculosis, and Malaria.
A Cornell researcher is working on a quick and affordable immune system test for people in the developing world. The test aims to help HIV/AIDS sufferers get proper treatment, potentially extending their lives by 10-15 years.
The NIAID has selected 60 U.S. and international institutions as HIV/AIDS Clinical Trials Units (CTUs) to conduct next-generation research on vaccines, prevention, and treatment. The CTUs will work together with clinical research networks to tackle critical research questions and accelerate progress against the HIV/AIDS pandemic.
The Microbicide Trials Network will conduct 17 clinical trials over seven years to determine if topical microbicides can prevent the sexual transmission of HIV in women. The network, supported by NIH, brings together international investigators and community partners to develop and evaluate microbicides.
A study by UCLA researchers found that only 41% of primary care providers offered advice on sexually transmitted infections or safe sex, while 36% had offered more than 20 HIV tests. The study suggests that providers are testing patients who present with symptoms rather than proactively offering early detection.
The National Institutes of Health has awarded grants to University Hospitals Case Medical Center for expanded HIV treatment development and pioneering advances in Microbicides Trials Network. This includes immunology laboratory funding at Case Western Reserve University School of Medicine and clinical trial research sites in Uganda.
Researchers at Rochester Institute of Technology are developing a micropump to administer drugs and gene-based therapy treatments for auditory dysfunction. The goal is to improve treatment and cure hearing loss, surpassing the limitations of existing hearing aids and cochlear implants.
A recent study published in Archives of Otolaryngology–Head & Neck Surgery found that outcomes following surgically implanted bone-anchored hearing aids are comparable for children younger than 5 years and those older than 5 years. Early and consistent stimulation of the cochlea is critical to a child's development of speech and language.
Recent studies published in major scientific journals reveal the molecular mechanisms behind Toxoplasma gondii's severity and its link to AIDS patients' dementia. The research provides a model for studying toxoplasmosis and related diseases, with potential applications for developing more effective treatments.
New research symposium in Perspectives on Politics examines the complex politics of HIV/AIDS in seven countries, highlighting key findings on state action, civil society mobilization, and their consequences. The symposium provides empirical and theoretical claims on the pandemic, shedding light on the diverse impact of HIV/AIDS on rela...
Researchers at the University of Utah have developed a new vaginal gel that turns into a gel-like coating when inserted, releasing an antiviral drug when exposed to semen. The 'molecular condom' has potential as a daily or monthly prevention method for AIDS, with hopes of being up to 90% effective.
Researchers discovered a potential strategy for treating metastatic melanoma by combining an antibody with radiation, leveraging insights from studying a fungus that causes infection in people with AIDS. The treatment approach shows promise in inhibiting tumor growth and inducing regression in mice with small melanoma tumors.
A new study by researchers at Fred Hutchinson Cancer Center and the University of Washington found that malaria increases HIV transmission to sex partners by up to 10 times. HIV-infected individuals are also more susceptible to malaria infections due to their compromised immune systems, fueling a rise in adult malaria-infection rates.
A large HIV/AIDS treatment trial found that interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause. The study used two levels of CD4+ T cells to guide therapy suspension and restarting, but participants receiving episodic therapy had a significantly increased risk of disease progression.
Between 2002 and 2030, life expectancy is expected to increase globally, with fewer child deaths under 5 years old. However, HIV/AIDS deaths are projected to rise, while tobacco-related diseases surpass them in prevalence.
The HIV/AIDS epidemic will hinder efforts to reduce extreme poverty and hunger, improve maternal health, and tackle infectious diseases. Researchers estimate that the epidemic could lower national GDP by up to 1.5% annually, with a greater impact on economic development in Africa.
The African-American community is facing a disproportionate impact of HIV/AIDS, with over half of all new diagnoses among this group. The National Minority AIDS Council recommends five policy solutions to address this disparity, including eliminating stigma against black MSM and reducing the role of injection drug use in sustaining the...
A novel home-based approach to AIDS care has been shown to improve adherence and response to antiretroviral therapy in rural Uganda. The study, published in The Lancet, found that good adherence was associated with sustained suppression of HIV during the first year of treatment.
The US has failed to promote effective family planning policies due to the Bush administration's inaction. Europe may need to take a lead in revitalizing global commitment to family planning, as population growth poses a greater threat to development than HIV/AIDS in many poor countries.
Researchers found that competition among T cells allows HIV to escape destruction and develop into full-blown AIDS. A new computer model suggests a polytopic vaccination strategy to combat this effect, which may prevent the final onset of AIDS by reducing immunodominance.
The study found that only 4-6% of a patient's CD4 cell loss rate can be explained by their presenting viral load, shifting the paradigm in predicting disease progression. The results suggest more complex scenarios of disease progression and hint at indirect processes through which HIV induces immune system damage.
The economic cost of HIV/AIDS in the US is estimated to be $36.4 billion annually, with minorities facing higher indirect costs due to lost productivity. The study suggests that universal access to antiretroviral therapy could reduce costs and improve outcomes.
A review of published research suggests that cigarette smoking increases the risk of contracting HIV and progressing to AIDS. The study found that five out of six studies concluded smokers were more likely to become HIV positive, with varying risks ranging from 60% to tripling.
A New York City analysis found that non-HIV-related deaths among people with AIDS increased by 32.8% from 1999 to 2004, with underlying causes including substance abuse and cardiovascular disease. The study suggests a shift in healthcare models to address physical and mental health needs is necessary to reduce these deaths.
A new study finds that concentrating antiretroviral drugs in urban areas could reduce new infections by up to 46%, but would violate basic ethical principles of treatment equity. The approach would also exacerbate urban/rural healthcare disparities.
Researchers found a molecular pathway that turns off immune cells targeting HIV, leading to exhaustion. Blocking this pathway restores function to these cells, suggesting a potential new approach to treating HIV infection.
Researchers like Barkley aim to understand the basic science of HIV-1 function and develop new therapies. The recent NIH grant supports a new area of AIDS research focusing on the chemical processes between the two pieces of reverse transcriptase protein that mobilize the HIV-1 virus.
A large-scale haplotype-mapping study aims to identify genetic factors that enable some HIV-infected individuals to suppress viral replication without treatment. The study, known as the Elite Controller Collaborative Study, hopes to develop a first-generation HIV vaccine that can successfully suppress viral levels.
A new study finds that a community-driven approach to distributing anti-AIDS medications is more equitable and effective than traditional top-down methods. Patients treated through this model showed significant increases in CD4 counts, indicating improved immune system function.
The International AIDS Vaccine Initiative proposes new scientific and policy initiatives to accelerate AIDS vaccine development, fostering capacity building in developing countries. The Blueprint highlights the need for a dynamic global research and development program with clear spending targets and equitable financial burden-sharing.
The International AIDS Society guidelines recommend treating HIV patients with an undetectable viral load using a combination of FUZEON and protease inhibitors. This approach is supported by recent clinical trials and has been endorsed by various health organizations, aiming to combat drug resistance and improve treatment outcomes.
A massive scale-up of HIV/AIDS treatment programs in Zambia showed favorable patient outcomes, demonstrating the feasibility of expansion in sub-Saharan Africa. The program's success was attributed to leadership and advocacy by the Zambian government, strict protocols for patient care, and large financial resources.
The International AIDS Society-USA Panel has updated guidelines for the treatment of adult HIV infection, recommending antiretroviral therapy for all symptomatic and asymptomatic adults with CD4 counts below 350/μL. The new guidelines also emphasize the importance of adherence to therapy and regular monitoring of plasma HIV-1 RNA levels.
A new CD-ROM containing more than 40 selected chapters from the HIV InSite Knowledge Base is being released to provide comprehensive HIV information in the developing world. The disk features a wide range of topics, including natural science, diagnosis and clinical management, transmission and prevention.
The Lancet has teamed up with PRODUCT RED to produce a (RED) issue devoted to HIV/AIDS, contributing $30,000 to the cause. The initiative aims to convince companies to develop RED products and donate profits to the Global Fund.
In sub-Saharan Africa, AIDS deaths are disproportionately affecting health professionals, particularly nurses and clinical officers. The study found that over a decade, death would claim more of these healthcare workers than resignation or normal retirement due to the disease.
A decade after HAART introduction, HIV/AIDS risk remains low for those starting treatment. However, a significant increase in tuberculosis (TB) cases among HAART patients has been observed since 1998, largely due to increased incidence of TB.
A Purdue University researcher has developed a molecule that can effectively combat drug-resistant strains of HIV, the virus that causes AIDS. The FDA recently approved the pill-based therapy, known as Darunavir, which is expected to be available to physicians this year.
Researchers discovered that HIV's surface glycoprotein interacts with CXCR4 on uninfected CD4+ T cells, triggering autophagy. This interaction leads to the death of uninfected bystander cells, contributing to the depletion of immune system cells in AIDS patients.
The HIV/AIDS epidemic in Latin America and the Caribbean is characterized by high prevalence rates, with over 3.5 million projected cases by 2015. The region's unique challenges include poverty, migration, and a lack of research into transmission patterns.
Global Plan to Stop TB 2006-2015 aims to increase joint TB/HIV programs, benefiting 3 million co-infected with antiretrovirals. Tuberculosis is a leading killer of people living with HIV, and collaboration between communities and governments is crucial to access effective interventions.
The Indian government's plan for controlling HIV is not yet fully implemented, and the consequences could be devastating. Experts call for increased access to care and treatment services, as well as strategic knowledge building, to mitigate the social fallout of the epidemic.
A study of 38 infant-mother pairs found that women who transmitted HIV to their babies had lower levels of a neutralizing antibody, suggesting its potential as a protective factor. The study suggests further research into the antibody's role could lead to an effective vaccine or passive antibody approaches.